Ulviprubart clinical trials

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis

This study is testing a new medicine called Ulviprubart for Inclusion Body Myositis (IBM). It aims to see if the medicine is safe and helps improve muscle strength and daily activities for people with IBM over 76 weeks, compared to a dummy treatment.